Cargando…

Murine peripheral blood prognostic biomarkers for tumor survival following combination aCTLA-4 and aPD-1 treatment

Detalles Bibliográficos
Autores principales:	Hilgart-Martiszus, Ian, McNamara, Michael, Redmond, William
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2015
Materias:	Poster Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4646051/ http://dx.doi.org/10.1186/2051-1426-3-S2-P91

Ejemplares similares

Combination OX40 agonism/CTLA-4 blockade with HER2 vaccination reverses T cell anergy and promotes survival in tumor-bearing mice
por: Linch, Stefanie, et al.
Publicado: (2015)

Biomarkers of survival statistics (boss) analytical platform
por: McNamara, Michael, et al.
Publicado: (2015)

Galectin-3 inhibition using novel inhibitor GR-MD-02 improves survival and immune function while reducing tumor vasculature
por: Linch, Stefanie, et al.
Publicado: (2015)

Adenovirus Armed With TNFa and IL2 Added to aPD-1 Regimen Mediates Antitumor Efficacy in Tumors Refractory to aPD-1
por: Cervera-Carrascon, Victor, et al.
Publicado: (2021)

Comparative analysis of the surface exposed proteome of two canine osteosarcoma cell lines and normal canine osteoblasts
por: Milovancev, Milan, et al.
Publicado: (2013)

NKTR-214 immunotherapy synergizes with radiotherapy to stimulate systemic CD8(+) T cell responses capable of curing multi-focal cancer
por: Walker, Joshua M, et al.
Publicado: (2020)

Immunocytokine augments local and abscopal response and animal survival when added to radiation and CTLA-4 checkpoint inhibition in a murine melanoma model
por: Morris, Zachary S, et al.
Publicado: (2015)

New results on MRS APDs
por: Akindinov, A, et al.
Publicado: (1997)

P16-05. Upregulation of PD-1 and CTLA-4 on HIV-specific T cells in HIV-infected infants
por: Nqoko, BS, et al.
Publicado: (2009)

Recent results on APDs for CMS ECAL
por: Puill, V
Publicado: (1999)

Avalanche photodiodes (APD) as proportional devices
por: Gilmore, R S, et al.
Publicado: (1994)

Tools for the Inspection of PWO//APD Gluing
por: Baccaro, Stefania, et al.
Publicado: (1998)

Preparative immunotherapy with anti-OX40 and anti-CTLA4 improves the response to chemotherapy
por: Friedman, David J, et al.
Publicado: (2014)

Analysis of survival following treatment of tumour-induced hypercalcaemia with intravenous pamidronate (APD).
por: Ling, P. J., et al.
Publicado: (1995)

Expression of PD-1 and CTLA-4 Are Negative Prognostic Markers in Renal Cell Carcinoma
por: Kahlmeyer, Andreas, et al.
Publicado: (2019)

Distinct immunologic changes in vivo following combination versus individual PD-1 or CTLA-4 checkpoint blockade in human cancer
por: Dhodapkar, Kavita, et al.
Publicado: (2014)

Image guided cryoablation of cancer with intra-tumoral injection of anti-CTLA-4 and PD-1 immune check-point inhibitors
por: Rosenberg, Mark A, et al.
Publicado: (2015)

ALICE Photon Spectrometer (PHOS). An assembled photo-detector of the PHOS: an APD with a low-noise preamplifier. The APD is seen.
Publicado: (2003)

Combination OX40 agonism/CTLA-4 blockade with vaccination reverses anergy and primes tumor-specific CD8 T cells in mice with spontaneous prostate cancer
por: Linch, Stefanie N, et al.
Publicado: (2013)

Combination immunotherapy with Interleukin-2 and CTLA-4 blockade decreases tumor growth and improves overall survival
por: Broucek, Joseph R, et al.
Publicado: (2013)

Characterization of irradiated APDs for picosecond time measurements
por: Centis Vignali, M, et al.
Publicado: (2018)

Hamamatsu APD for CMS ECAL: Quality insurance
por: Bailleux, D, et al.
Publicado: (2004)

Wavelength dependence of avalanche photodiode (APD) parameters
por: Kirn, T, et al.
Publicado: (1997)

Mitigation of Anomalous APD signals in the CMS ECAL
por: Petyt, David Anthony
Publicado: (2012)

Mitigation of anomalous APD signals in the CMS ECAL
por: Bialas, W, et al.
Publicado: (2013)

CMS ECAL APD quality assurance facility
por: Deiters, K, et al.
Publicado: (2000)

APD performance in a luminosity monitor at LEP
por: Bartolomé, E, et al.
Publicado: (2000)

The Power Supply System for CMS-ECAL APDs
por: Bartoloni, A
Publicado: (2001)

APD Properties and Recovery from Radiation Damage
por: Baccaro, Stefania, et al.
Publicado: (1997)

Scintillation counter with MRS APD light readout
por: Akindinov, A., et al.
Publicado: (2006)

APD Power Control for the ALICE PHOS Prototype
por: Sibiryak, I, et al.
Publicado: (2005)

The construction of the CMS ECAL: avalanche photodiodes (APDs)
Publicado: (2005)

The CMS electromagnetic calorimeter: Crystals and APD productions
por: Bloch, P
Publicado: (2010)

Role of APD-Ribosylation in Bone Health and Disease
por: Wang, Chun, et al.
Publicado: (2019)

Combined targeting of co-stimulatory (OX40) and co-inhibitory (CTLA-4) pathways elicits potent effector T cells capable of driving robust anti-tumor immunity
por: Redmond, William L, et al.
Publicado: (2013)

Overall survival of metastatic melanoma patients treated with HD IL-2 followed by immune checkpoint blockade of the CTLA-4 or the PD-1 pathways: analysis of data on the current use of HD IL-2
por: Wong, Michael KK, et al.
Publicado: (2015)

Complex Interaction Between Low-Frequency APD Oscillations and Beat-to-Beat APD Variability in Humans Is Governed by the Sympathetic Nervous System
por: Duijvenboden, Stefan Van, et al.
Publicado: (2020)

CTLA-4 based therapy (MDX-010)
por: Korman, A
Publicado: (2003)

Therapeutic efficacy of combined blockade of CTLA-4 +/- PD-L1 +/- IDO is associated with re-activation of T cells directly within the tumor microenvironment
por: Spranger, Stefani, et al.
Publicado: (2013)

Updated efficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in metastatic melanoma patients previously treated with anti-PD-1 therapy
por: Prithviraj, Prashanth, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_86123d01ija02p3j4mfre873av